Perbandingan Kejadian Fatty Liver pada Ultrasonografi Penderita Kanker Payudara Dengan dan Tanpa Terapi Tamoxifen

Abstract

Background: Tamoxifen is a Selective Estrogen Reseptor Modulators, serves as an anti-estrogen to block the e?ects of estrogen on breast cancer tissue. Tamoxifen interferes with fat metabolism which lead to fatty liver. Ultrasonography is main modality to detect the presence of fatty liver, which is divided into degrees of 0, 1, 2 and 3. Fat infltration into liver blood vessels causes a decrease in intrahepatic vascular compliance which can be examined using Doppler hepatic vein spectral ultrasound, into a triphasic, biphasic or monophasic waveform.Objectives: To compare the degree of fatty liver and hepatic vein spectral waveform and its correlation in ultrasonography of breast cancer patients with and without tamoxifen therapy.Materials and Methods: Observational cross-sectional study with non-random consecutive sampling. This study used questionnaires and grey-scale ultrasound examination of the liver and right hepatic vein spectral Doppler ultrasound. Statistical analysis used was K-S test.Results: Mode of breast cancer diagnosed age range was 50-60 y.o. and the youngest was 28 y.o. None of the subjects was obese. The mean use of tamoxifen was 19+5,87 months. There is an increase in the incidency of degree 1 and 3 fatty liver in breast cancer patients with tamoxifen therapy, but this was not statistically signifcant. Hepatic vein spectral abnormalities with monophasic waveforms also increased in tamoxifen therapy compared without tamoxifen therapy, but this was not statistically signifcant.Conclusions: Increased incidency of degree 1 and 3 fatty liver and abnormal spectral monophasic waveform in breast cancer patients with tamoxifen were not statistically signifcant. There was no signifcant correlation between the incidency of degree of fatty liver and hepatic vein spectral waveform.